Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers.

@article{Ho2011PhaseIP,
  title={Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers.},
  author={Yunn-Fang Ho and Wan-Chen Lu and Russel Rhei-Long Chen and Anthony S. K. Cheng and Kun-Huei Yeh},
  journal={Anti-cancer drugs},
  year={2011},
  volume={22 3},
  pages={
          290-8
        }
}
The primary aim of the high-dose 5-fluorouracil (5-FU) and leucovorin (LV; HDFL48) phase I study was to determine the maximum tolerated dose and dose-limiting toxicity of 5-FU and LV with modified tri-monthly 48-h continuous infusion of high-dose 5-FU/LV in patients with metastatic colorectal cancer. The study also determined the pharmacokinetic parameters of 5-FU, especially steady-state plasma and bone marrow (BM) concentrations. Eligibility included serum triglyceride of more than or equal… CONTINUE READING
BETA